Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
|Articles|September 1, 2004
The American Journal of Managed Care
- September 2004
- Volume 10
- Issue 9
HMORN Abstracts
Advertisement
Cancer
Cardiovascular
Evaluating Care Delivery
Genetics
Health Economics
Information Technology
Lifestyle/Health Behavior
Pharmacoepidemiology
Prevention & Screening
Racial Disparities
Women's Health
Miscellaneous
Other
Articles in this issue
about 22 years ago
Consumers' Use of the Internet for Health Insuranceabout 22 years ago
Taking Stock at 2 Years - Continuing the Journeyabout 22 years ago
The Influence of Year-end Bonuses on Colorectal Cancer ScreeningAdvertisement
Related to this article
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5